ASCO 2019 Press Releases

Viewing 1-6 of 6 articles

Janssen Seeks to Expand Use of ERLEADA® (apalutamide) in the Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer

Astellas and Seattle Genetics Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer

ASCO 2019: TITAN: Apalutamide Meets Dual Primary Endpoints, Shows Good Tolerability in Metastatic Hormone Sensitive Prostate Cancer

ASCO Announces Top Studies to Be Presented at 2019 Annual Meeting

Dana-Farber Researchers Present Findings in More than 70 Research Studies at ASCO Annual Meeting 2019

Myriad Genetics to Present Multiple Studies at the 2019 American Society of Clinical Oncology Annual Meeting